New hope for devastating mitochondrial disease
NCT ID NCT06644534
Summary
This study is testing whether an oral medicine called TTI-0102 can help control symptoms and improve daily function in people with MELAS, a rare and serious genetic disorder that affects energy production in the body. About 12 participants, aged 16-60 with moderate disease, will take either the real medicine or a placebo for 6 months. Researchers will measure changes in walking distance, fatigue, and quality of life to see if the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITOCHONDRIAL ENCEPHALOMYOPATHY, LACTIC ACIDOSIS AND STROKE-LIKE EPISODES (MELAS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Angers University Hospital Center (CHU Angers)
RECRUITINGAngers, 49100, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Radboud University Medical Center
RECRUITINGNijmegen, 6500 HB, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.